Structural basis of reduced susceptibility to ceftazidime- avibactam and cefiderocol in enterobacter cloacae due to AmpC R2 loop deletion

Akito Kawai, Christi L. McElheny, Alina Iovleva, Ellen G. Kline, Nicolas Sluis-Cremer, Ryan K. Shields, Yohei Doi

研究成果: ジャーナルへの寄稿学術論文査読

54 被引用数 (Scopus)

抄録

Ceftazidime-avibactam and cefiderocol are two of the latest generation β-lactam agents that possess expanded activity against highly drug-resistant bacteria, including carbapenem-resistant Enterobacterales. Here, we show that structural changes in AmpC β-lactamases can confer reduced susceptibility to both agents. A multidrug-resistant Enterobacter cloacae clinical strain (Ent385) was found to be resistant to ceftazidime-avibactam and cefiderocol without prior exposure to either agent. The AmpC β-lactamase of Ent385 (AmpCEnt385) contained an alanine-proline deletion at positions 294 and 295 (A294_P295del) in the R2 loop. AmpCEnt385 conferred reduced susceptibility to ceftazidime-avibactam and cefiderocol when cloned into Escherichia coli TOP10. Purified AmpCEnt385 showed increased hydrolysis of ceftazidime and cefiderocol compared to AmpCEnt385Rev, in which the deletion was reverted. Comparisons of crystal structures of AmpCEnt385 and AmpCP99, the canonical AmpC of E. cloacae complex, revealed that the two-residue deletion in AmpCEnt385 induced drastic structural changes of the H-9 and H-10 helices and the R2 loop, which accounted for the increased hydrolysis of ceftazidime and cefiderocol. The potential for a single mutation in ampC to confer reduced susceptibility to both ceftazidime-avibactam and cefiderocol requires close monitoring.

本文言語英語
論文番号e00198-20
ジャーナルAntimicrobial agents and chemotherapy
64
7
DOI
出版ステータス出版済み - 07-2020

All Science Journal Classification (ASJC) codes

  • 薬理学
  • 薬理学(医学)
  • 感染症

フィンガープリント

「Structural basis of reduced susceptibility to ceftazidime- avibactam and cefiderocol in enterobacter cloacae due to AmpC R2 loop deletion」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル